Recommand
GLP-1 receptor agonists for NAFLD treatment in patients with and without type 2 diabetes: an updated meta-analysis
By activating both receptors, tirzepatide enhances insulin secretion, reduces glucagon release, and promotes weight loss
Recent studies demonstrate a strong correlation between GLP-1 agonists and the treatment of neurodegenerative diseases by reducing amyloid-beta and tau pathology in the hippocampus, thereby making them a promising target for Alzheimers disease treatment (Hlscher, 2014
Testosterones cardiac reputation, for years the big fear, mostly held up to scrutiny: in a trial of more than 5,000 men at high cardiovascular risk, TRT did not cause more heart attacks than placebo (Lincoff, New England Journal of Medicine, 2023)
funding acquisition